紫杉醇脂质体与紫杉醇联合顺铂治疗晚期非小细胞肺癌对比研究被引量：25

Comparison of paclitaxel liposome and paclitaxel plus cisplatin in patients with non-small cell lung cancer

下载PDF

导出

摘要目的探讨紫杉醇脂质体与紫杉醇联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法晚期NSCLC患者72例,随机分为试验组与对照组,试验组采用紫杉醇脂质体135mg/m2,对照组采用紫杉醇135mg/m2化疗,两组均联合顺铂,21天为1个周期,治疗2个周期后评价疗效。记录近期疗效与治疗期间毒副反应。结果试验组有效率为41.7%(15/36),临床受益率为77.7%(28/36),对照组有效率为38.9%(14/36),临床受益率为72.2%(26/36),两组差异均无统计学意义(P>0.05)。白细胞减少和血小板减少的发生率两组差异无统计学意义(P>0.05),脱发、腹泻、便秘及呼吸困难的发生率两组差异亦无统计学意义(P>0.05),但试验组恶心、呕吐、皮疹、肌肉痛的发生率明显低于对照组(P<0.05)。结论紫杉醇脂质体联合顺铂治疗晚期NSCLC近期疗效确切有效,毒副反应较紫杉醇联合顺铂化疗为轻。 Objective To investigate the efficacy and safety of paclitaxel liposome regimen on non-small cell lung cancer（NSCLC）compared with traditional paclitaxel plus cisplatin（DDP）in patients.Methods Seventy-two NSCLC patients were randomized into a test group,given paclitaxel liposome 135mg/m2 plus DDP 25mg/m2,and a control group,given paclitaxel 135mg/m2 plus DDP 25mg/m2.The two groups received these regiments for 2 cycles.Results The overall response rates were 41.7% vs.38.9%,and the disease control rates were 77.7% vs.72.2% in the test group and control group（P0.05）.The rates of neutropenia and thrombocytopenia were not significantly different in the test group and control group whereas more patients in the control group than in the test group suffered from nausea and vomiting,erythra,courbature（P0.05）,and the rates of lipsotrichia diarrhoea and dyspnea were similar between the two groups（P0.05）.Conclusion Paclitaxel liposome combined with DDP is an effective treatment regimen with lower incidence of side effects,compared with paclitaxel plus DDP.

作者赵敏张红斌梁健梁香存才虹美郭素敏

机构地区河北省胸科医院肿瘤科

出处《临床肿瘤学杂志》 CAS 2010年第4期343-345,共3页 Chinese Clinical Oncology

关键词非小细胞肺癌紫杉醇脂质体紫杉醇顺铂化学治疗 Non-small cell lung cancer Paclitaxel liposome Paclitaxel Cisplatin Chemotherapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1Belotti D,Vergani V,Drudis T,et al.The microtubule-affecting drug paclitaxel has antiangiogenic activity[J].Clin Cancer Res,1996,2:1843-1849.
2Scagliotti G.Optimizing chemotherapy for patients with advanced non-small cell lung cancer[J].J Thorac Oncol,2007,2 (Suppl):86-91.
3Singh S,Dash AK.Paclitaxel in cancer treatment:perspectives and prospects of its delivery challenges[J].Crit Rev Ther Drug Carrier SySt,2009,26(4):333-372.
4Schmitt-Sody M,Strieth S,Krasnici S,et al.Neovascular targeting therapy:paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy[J].Clin Cancer Res,2003,9:2335-2341.
5Treat J,Damjanov N,Huang C,et al.Liposomal-encapsulated chemotherapy:preliminary results of a phaseⅠstudy of a novel liposomal paclitaxel[J].Oncology,2001,15:44-48.
6Zhang Q,Huang XE,Gao LL.A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors[J].Biomed Pharmacother,2009,63(8):603-607.
7Holvoet C,Vander Heyden Y,Lories G,et al.Preparation and evaluation of paclitaxel-containing liposomes[J].Pharmazie,2007,62(2):126-132.